Legislative Assembly for the ACT: 2018 Week 6 Hansard (7 June) . . Page.. 2341 ..
(4) What has been the final cost of the duplication.
Ms Fitzharris: The answer to the member's question is as follows:
(1) The cost of relocating the ActewAGL pipes were as follows:
(a) Gas relocation - $0.950 million;
(b) Water main relocation - $0.770 million; and
(c) ActewAGL High Voltage line relocation - $0.198 million.
(2) (a) Estimated Costs for the relocation of these utility assets were known prior to the commencement of construction. (b) The costs associated with the relocation of these utility assets was included in the original project budget and formed part of the construction contract.
(3) The original budget for the Ashely Drive Duplication Stage 2 was $ 24.7 million and Stage 3 $3.5 million.
(4) The final construction cost for the Ashley Drive Duplication Stage 2 and Stage 3 will be within this project budget. As the project is still active the exact final project costs is yet to be determined.
Note: The above figures are current as of 15 May 2018.
Questions without notice taken on notice
Ms Fitzharris (in reply to a question and a supplementary question by Mrs Kikkert on Thursday, 22 March 2018):
1. The Government understands that cancer patients do incur out-of-pocket expenses however, an actual figure is unable to be provided due to the variable treatment pathways and treatment choices made by each individual patient.
2. In the 2017 Breast Cancer Network Australia publication "The Financial Impact of Breast Cancer" these key areas of cost were identified: travel for treatment, supportive medications, counselling, accommodation, diagnostic imaging and radiation treatment.
There is a requirement for cancer patients in the public and private systems to make a co-payment for chemotherapy and other supportive medications in the ACT. Most medications are on the Pharmaceutical Benefits Scheme (PBS) with a usual script fee.
In the ACT, patients may choose to access the private health system for their care. This can be of significant cost to the patient. This can occur from time of diagnosis to post treatment care.